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Abstract
Background Chronic inflammatory demyelinating poly-
neuropathy (CIDP) is the most common treatable
acquired chronic polyneuropathy. Corticosteroids, plas-
mapheresis and intravenous immunoglobulins (IVIG)
have been shown to be effective in randomized con-
trolled clinical trials and IVIG is widely used as a first-
line initial and maintenance treatment for CIDP. Studies
in animal models of autoimmune diseases indicated that
the inhibitory Fc-gamma receptor FcγRIIB, expressed on
myeloid cells and B cells, is required for the anti-
inflammatory activity of IVIG.
Summary We found that untreated patients with CIDP,
compared to demographically matched healthy controls,
show lower FcγRIIB expression levels on naïve B cells and
fail to upregulate or to maintain upregulation of FcγRIIB as
B cells progress from the naive to the memory compart-
ment. Furthermore, FcγRIIB protein expression is upregu-
lated on B cells and monocytes following clinically
effective IVIG therapy suggesting that impaired expression
of the inhibitory FcγR in CIDP can, at least partially, be
restored by IVIG treatment. In B cells, FcγRIIB transduces
an inhibitory signal upon colligation with the B cell
receptor, thereby preventing B cells with low affinity or
self-reactive receptors from entering the germinal center
and becoming IgG positive plasma cells. Our data suggest
that this late B cell differentiation checkpoint is impaired in
CIDP. Modulating FcγRIIB function might be a promising
approach to efficiently limit antibody-mediated immunopa-
thology in CIDP.
Keywords Chronic inflammatory demyelinating
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CIDP: Pathophysiological Aspects
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is an acquired immune-mediated disease of the
peripheral nervous system. It is the most common form of a
heterogeneous group of immune-mediated and, in many
cases, well-treatable peripheral neuropathies [1]. The
estimated prevalence rate of CIDP differs between 1.61
and 8.9 per 100,000 [2, 3]. Although CIDP occurs at any
age, the peak incidence is between 40 and 60 years. The
most common form of CIDP causes symmetrical progres-
sive or relapsing weakness that affects proximal and distal
muscles with concomitant distal sensory involvement and
areflexia [4, 5].
Several mechanisms such as inflammation, demyelin-
ation, axonal damage, and repair mechanisms contribute
sequentially or simultaneously to the pathophysiology of
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CIDP. The disease is believed to be triggered and main-
tained by an immune response against yet unidentified
autoantigens within the peripheral nervous system. In
experimental in vivo models for autoimmune neuropathies,
such as experimental autoimmune neuritis (EAN), the
genetic background of the animal will determine the choice
of induction of immune response. Immunization with entire
myelin homogenates, the major myelin adhesion molecule
P0, the fatty acid binding protein P2, myelin basic protein,
or with gangliosides that are prevalent in axonal mem-
branes leads to the development of demyelinating or axonal
inflammatory neuropathies. Injection of myelin-reactive T
cells is sufficient to induce adoptive-transfer EAN in
susceptible hosts [6].
Proinflammatory T helper cell type 1 (Th1) signature
cytokines such as the chemokine receptor CXCR-3,
interferon-γ inducible protein-10, and monokine induced
by interferon-γ are detectable in sural nerve biopsies from
patients with CIDP and other autoimmune neuropathies [7].
This suggests that, similar to other autoimmune diseases,
Th1 cells orchestrate and maintain peripheral nerve damage
in CIDP.
Humoral immune responses are thought to play a crucial
role in mediating peripheral nerve damage and represent
important pharmacological targets in patients with CIDP.
Sera and immunoglobulin G (IgG) antibodies from patients
induce peripheral demyelination in host animals [8] and can
increase the permeability of the blood–nerve barrier and
impair nerve conduction in various models of peripheral
neuropathies [6]. Removal of humoral immune mediators
by plasma exchange therapy as well as through intravenous
immunoglobulin (IVIG) is considered first-line treatments
in patients with CIDP [9, 10].
Efficacy of IVIG in CIDP: Evidence from Clinical Trials
Corticosteroids, plasmapheresis, and IVIG have been
shown to be effective in short-term prospective randomized
controlled trials (RCTs). Rituximab, alemtuzumab, etaner-
cept, interferon-β, interferon-α, mycophenolate mofetil, or
stem cell transplants were efficacious in individual cases.
Plasma-exchange therapy and cyclophosphamide are usually
reserved for rapid progressive courses [1].
Although widely used in clinical practice, a significant
number of patients with CIDP do not respond to cortico-
steroids [11]. Moreover, long-term administration of corti-
costeroids is associated with numerous and potentially
severe side effects. IVIG proved to be safe and potent in
several RCTs in treatment-naive patients as well as in
steroid- or plasma-exchange nonresponders [10, 12–16]. Of
53 patients included in a short-term RCT [16], 30 were
treated with IVIG and 23 with placebo, the latter being
clearly inferior. Hughes et al. [15] studied the effect of
IVIG (2 g/kg over 1 to 2 days) vs. steroids (60 mg/day
tapered to 10 mg/day) in a 6-week RCT crossover design.
The patients clearly improved in both treatment arms.
Although no significant difference could be detected
between both treatment regimens, a trend toward a better
response of IVIG was observed.
A recent clinical trial addressed short-term as well as
long-term effects of caprylate/chromatography purified
IVIG (IGIV-C) in comparison with placebo in CIDP
[10]. Patients received placebo or a loading dose of 2 g/kg
over 2 to 4 consecutive days, followed by regular
infusions of 1 g/kg over 1 to 2 days every 3 weeks for
up to 24 weeks. The primary outcome was the percentage
of patients who had maintained an improvement from
baseline to week 24. Patients who showed an improve-
ment and completed 24 weeks of treatment were eligible
to be randomly reassigned in a blinded 24-week extension
phase.
During the first period, 32 of 59 (54%) patients
treated with IGIV-C and 12 of 58 (21%) patients who
received placebo had an improvement according to a
clinical disability score (INCAT) that was maintained to
week 24 (treatment difference 33.5%; 95% CI, 15.4-51.7;
P=0.0002). During the extension phase, the participants
who continued to receive IGIV-C had a longer time to
relapse than the patients who were treated with placebo.
This indicated prolonged benefits of maintenance treat-
ment with IVIG in those patients with CIDP who initially
responded to an IVIG loading dose. Thus, several
prospective placebo-controlled clinical trials have demon-
strated consistently that administration of IVIG improves
neurologic disability and provides long-term benefits to
patients with CIDP.
Anti-inflammatory Effects of IVIG: Fc is the Key
An IVIG preparation consists of the pooled serum IgG
fraction from thousands of donors. Many mechanisms
have been proposed to be involved in the anti-
inflammatory activity of this therapeutic agent. Broadly
speaking, these can be divided into two major path-
ways: either dependent on the F(ab)2 or the Fc fragment
of the IgG molecule. CD95-specific antibodies, for
example, have been reported to be present in IVIG
preparations and might interfere with the proapoptotic
pathways essential for the pathology involved in a
variety of skin-blistering diseases such as toxic epider-
mal necrolysis [17].
For most cases where suitable in vivo model systems
were available, however, there is clear evidence that the
IgG Fc fragment is the predominant mediator of the anti-
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inflammatory activity. Thus, in animal models of immune
thrombocytopenic purpura (ITP), rheumatoid arthritis, and
nephritis, the Fc fragment but not the F(ab)2 fragment
interfered with autoantibody-triggered inflammation [18–20].
Similarly, the isolated IVIG Fc fragment prevented platelet
depletion in human ITP patients, thus supporting the
general importance of this Fc-dependent anti-inflammatory
pathway [21].
Immunoglobulin G antibodies can trigger two major pro-
inflammatory pathways via their Fc fragment. First, they
can initiate activation of the complement pathway, which
results in the generation of the proinflammatory anaphyla-
toxins C3a and C5a, and the lytic membrane attack
complexes [22]. Second, IgG autoantibodies can cross-
link cellular Fc receptors specific for IgG (FcγRs) that are
present on most innate immune effector cells, including
neutrophils, mast cells, and macrophages.
The family of FcγRs consists of several activating
members (FcγRIA, IIA, IIC, and IIIA in humans; FcγRI,
III, and IV in mice) and one inhibitory member (FcγRIIB),
which are coexpressed on most innate immune effector
cells. Thus, immune complexes will trigger both activating
and inhibitory signalling pathways. Depending on the
affinity of the different IgG subclasses for the inhibitory
and the activating FcγRs, a more or less pronounced response
will be initiated [23].
In addition to cells of the innate immune system, the
inhibitory FcγRIIB is also expressed on B cells in which it
transduces an inhibitory signal upon colligation with the B
cell receptor. This action prevents B cells with low affinity
or self-reactive receptors from entering the germinal center
and becoming IgG-positive plasma cells [24]. Mice lacking
FcγRIIB expression spontaneously develop autoimmune
disease [25], and restoration of decreased FcγRIIB expres-
sion on activated B cells in autoimmune-susceptible mice
restores immunological tolerance [24]. Autoimmune-prone
mouse strains such as BXSB, NOD, and NZM carry a
promoter polymorphism in the FcγRIIB gene that results in
decreased protein expression [26]. Decreased FcγRIIB
expression or nonfunctional FcγRIIB variants have been
shown to be associated with the development and severity
of systemic lupus erythematosus in several human popula-
tions [24, 27]. Notably, this inhibitory receptor is required
for anti-inflammatory activity of IVIG because disruption
of this protein by genetic deletion or via blocking anti-
bodies reverses the therapeutic effects of IVIG in a variety
of autoimmune animal models [19, 28–30].
Taken together, the inhibitory Fc-gamma receptor
FcγRIIB plays a critical role in the balance of tolerance
and autoimmunity and is required for the anti-inflammatory
activity of IVIG in a variety of murine disease models. Less
well understood, however, is the function of FcγRIIB and
its regulation by IVIG in human autoimmune diseases.
Mechanisms of IVIG in CIDP
To address the function of FcγRIIB in an antibody-
mediated IVIG-responsive human disease, we determined
the expression profile of FcγRIIB on peripheral blood
monocytes and B cells and explored its regulation follow-
ing IVIG therapy as a possible pathomechanism in patients
with CIDP [31].
We found that untreated patients with CIDP, compared
with demographically matched healthy controls, showed
consistently lower B cell expression levels of FcγRIIB. The
reduction in FcγRIIB expression was stronger in the
CD19+CD27+ memory compared with the CD19+CD27-
naive B cell compartment. This was due to a failure of
patients with CIDP to upregulate or to maintain upregula-
tion of FcγRIIB as B cells became memory cells. FcγRIIB
expression was unchanged in CD14+ blood myeloid cells.
Next, we determined FcγRIIB expression levels on circulat-
ing monocytes and B cells in treatment-naive patients with
CIDP before and 2 to 3 weeks following clinically effective
IVIG administration (2 g/kg body weight over 5 days).
Compared with baseline levels, IVIG led to a significant
upregulation of FcγRIIB expression on naive B cells,
memory B cells, and to a lesser degree, blood monocytes
in most of the patients. This indicates that the impaired
expression of the inhibitory FcγRIIB in CIDP can, at least
partially, be restored by clinically effective IVIG treatment.
Furthermore, these findings suggest that results obtained
in murine model systems with respect to the mechanism of
IVIG activity in vivo might be transferable to humans.
These data also suggest that FcgRIIB expression mediates
immunomodulatory effects of IVIG in CIDP by raising the
activation threshold for B lineage and myeloid cells.
Outlook
New data from mouse models of rheumatoid arthritis
suggest that certain IgG glycosylation variants might be of
great importance for FcgRIIB binding and the anti-
inflammatory activity of IVIG. Glycosylation of IgG-Fc
contributes both to the stability and biological activity of
antibody molecules and is essential for effector functions
mediated through FcR. IgG and other immunoglobulin
isotypes are composed of an amino acid backbone that
contains a sugar moiety attached to an asparagine 297
residue in the antibody constant region (N297) [32]. This
moiety consists of a heptameric core sugar structure with
variable amounts of branching and terminal sugar residues
such as galactose, sialic acid (SA), N-acetylglucosamine,
and fucose. The importance of IgG glycosylation is high-
lighted by the loss of therapeutic activity of deglycosylated
IVIG preparations [30]. Conversely, IVIG preparations and
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isolated Fc fragments enriched for terminal SA residues have
more than a tenfold higher anti-inflammatory activity [33].
More than 30 different antibody glycovariants have been
detected in human serum, with about 25% of them located
in the IgG-G0 glycoform, that is, without terminal SA or
galactose residues. Notably, IgG-G0 glycoforms are mark-
edly increased in patients with rheumatoid arthritis [34].
Especially during acute disease phases, a significant
reduction in terminal SA residues in serum and antigen-
specific antibodies can be observed, and the IgG-G0
glycovariant constitutes more than 50% of serum IgG
[34]. Similar observations were made in experimental
models of other autoimmune diseases [30, 35–39].
Thus, investigating Fc glycosylation in patients with
CIDP as well as in other autoimmune diseases with a strong
humoral immune component could provide new insights
into mechanisms of antibody-mediated tissue damage.
Although there are still many open questions regarding
the mechanisms of this novel pathway, clinical trials to test
the safety and therapeutic efficacy of SA-rich IVIG are
currently being initiated. These trials might provide
important information about the function of IgG glycosyl-
ation in the human immune system.
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